Literature DB >> 9049304

Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation.

J Gille1, R A Swerlick, S W Caughman.   

Abstract

The endothelial cell-specific mitogen vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) represents a central regulator of cutaneous angiogenesis. Increased VPF/VEGF expression has recently been reported in psoriatic skin and healing wounds, both conditions in which transforming growth factor-alpha (TGF alpha) and its ligand, the epidermal growth factor receptor, are markedly up-regulated. Since TGF alpha strongly induces VPF/VEGF synthesis in keratinocytes, TGF alpha-mediated VPF/VEGF expression is likely to play a significant role in the initiation and maintenance of increased vascular hyperpermeability and hyperproliferation in skin biology. The objectives of the present studies were to determine the molecular mechanisms responsible for TGF alpha-induced transcriptional activation of the VPF/VEGF gene. We have identified a GC-rich TGF alpha-responsive region between -88 bp and -65 bp of the VPF/VEGF promoter that is necessary for constitutive and TGF alpha-inducible transcriptional activation. In electrophoretic mobility shift assays, this region binds Sp1-dependent protein complexes constitutively and an additional TGF alpha-inducible protein complex that is distinct from Sp1 protein. Both AP-2 and Egr-1 transcription factors were detected as components of the TGF alpha-inducible protein complex in supershift EMSA studies. In co-transfection studies, an AP-2 but not an Egr-1 expression vector activated VPF/VEGF transcription, thus indicating that AP-2 protein is functionally important in TGF alpha-induced VPF/VEGF gene expression. By clarifying regulatory mechanisms that are critical for angiogenic processes in the skin, these studies may form the basis for new therapeutic strategies to modulate VPF/VEGF expression in cutaneous inflammation and wound healing.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049304      PMCID: PMC1169676          DOI: 10.1093/emboj/16.4.750

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  38 in total

1.  An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2.

Authors:  R Buettner; P Kannan; A Imhof; R Bauer; S O Yim; R Glockshuber; M W Van Dyke; M A Tainsky
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

2.  Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions.

Authors:  L F Brown; S M Olbricht; B Berse; R W Jackman; G Matsueda; K A Tognazzi; E J Manseau; H F Dvorak; L Van de Water
Journal:  J Immunol       Date:  1995-03-15       Impact factor: 5.422

3.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.

Authors:  B Millauer; L K Shawver; K H Plate; W Risau; A Ullrich
Journal:  Nature       Date:  1994-02-10       Impact factor: 49.962

4.  Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies.

Authors:  T M Sioussat; H F Dvorak; T A Brock; D R Senger
Journal:  Arch Biochem Biophys       Date:  1993-02-15       Impact factor: 4.013

5.  Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium.

Authors:  T P Quinn; K G Peters; C De Vries; N Ferrara; L T Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

6.  Localization of transforming growth factor-alpha RNA and protein in the skin of psoriatic patients receiving therapy.

Authors:  P Watts; G S Stables; R J Akhurst; R M Mackie
Journal:  Br J Dermatol       Date:  1994-07       Impact factor: 9.302

7.  Human keratinocytes express the three major splice forms of vascular endothelial growth factor.

Authors:  C Ballaun; W Weninger; A Uthman; H Weich; E Tschachler
Journal:  J Invest Dermatol       Date:  1995-01       Impact factor: 8.551

8.  Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes.

Authors:  I Stein; M Neeman; D Shweiki; A Itin; E Keshet
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

Review 9.  Molecular mechanisms of developmental and tumor angiogenesis.

Authors:  K H Plate; G Breier; W Risau
Journal:  Brain Pathol       Date:  1994-07       Impact factor: 6.508

10.  Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis.

Authors:  M Detmar; L F Brown; K P Claffey; K T Yeo; O Kocher; R W Jackman; B Berse; H F Dvorak
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  46 in total

1.  Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.

Authors:  A E Lenferink; J F Simpson; L K Shawver; R J Coffey; J T Forbes; C L Arteaga
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

Review 2.  Molecular interactions of 'high risk' human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression.

Authors:  Oishee Chakrabarti; Sudhir Krishna
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

3.  EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.

Authors:  R Bonavia; M M Inda; S Vandenberg; S-Y Cheng; M Nagane; P Hadwiger; P Tan; D W Y Sah; W K Cavenee; F B Furnari
Journal:  Oncogene       Date:  2011-12-05       Impact factor: 9.867

4.  Synergistic up-regulation of vascular endothelial growth factor (VEGF) expression in macrophages by adenosine A2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter.

Authors:  Madhuri Ramanathan; Grace Pinhal-Enfield; Irene Hao; Samuel Joseph Leibovich
Journal:  Mol Biol Cell       Date:  2006-10-25       Impact factor: 4.138

5.  Loss of transcription factor early growth response gene 1 results in impaired endochondral bone repair.

Authors:  Marie K Reumann; Olga Strachna; Sarah Yagerman; Daniel Torrecilla; Jihye Kim; Stephen B Doty; Lyudmila Lukashova; Adele L Boskey; Philipp Mayer-Kuckuk
Journal:  Bone       Date:  2011-06-25       Impact factor: 4.398

6.  Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo.

Authors:  Di Jia; Sean M Hasso; Joanne Chan; Domenic Filingeri; Patricia A D'Amore; Lori Rice; Christine Pampo; Dietmar W Siemann; David Zurakowski; Scott J Rodig; Marsha A Moses
Journal:  Blood       Date:  2012-12-03       Impact factor: 22.113

7.  The transcription factor Net regulates the angiogenic switch.

Authors:  Hong Zheng; Christine Wasylyk; Abdelkader Ayadi; Joseph Abecassis; Jack A Schalken; Hermann Rogatsch; Nicolas Wernert; Sauveur-Michel Maira; Marie-Christine Multon; Bohdan Wasylyk
Journal:  Genes Dev       Date:  2003-09-15       Impact factor: 11.361

8.  Chronic systemic hypoxia causes intra-retinal angiogenesis.

Authors:  Alex J Shortt; Katherine Howell; Colm O'Brien; Paul McLoughlin
Journal:  J Anat       Date:  2004-11       Impact factor: 2.610

9.  Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17.

Authors:  Mark Katakowski; Feng Jiang; XuGuang Zheng; Jorge A Gutierrez; Alexandra Szalad; Michael Chopp
Journal:  Cancer Sci       Date:  2009-05-18       Impact factor: 6.716

10.  CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma.

Authors:  Vladislava O Melnikova; Andrey S Dobroff; Maya Zigler; Gabriel J Villares; Russell R Braeuer; Hua Wang; Li Huang; Menashe Bar-Eli
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.